Top

Langenbeck's Archives of Surgery

Published in:

01-12-2011 | Original Article

Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1

Authors: Caroline L. Lopez, Jens Waldmann, Volker Fendrich, Peter Langer, Peter H. Kann, Detlef K. Bartsch

Published in: Langenbeck's Archives of Surgery | Issue 8/2011

Abstract

Purpose

This study was made to evaluate long-term results of an aggressive surgical approach for pancreaticoduodenal neuroendocrine neoplasms (pNENs) in patients with multiple endocrine neoplasia type 1 (MEN1).

Methods

MEN1 patients with either biochemical evidence of functioning or non-functioning pNENs larger than 1 cm in size on imaging underwent duodenopancreatic surgery. Since 1997, patients were followed annually by biochemical testing and imaging studies.

Results

Thirty-eight genetically confirmed MEN1 patients underwent duodenopancreatic resection for functioning (n = 22) or non-functioning (n = 16) pNENs, nine patients were yet not operated. Malignant disease occurred in 12 (35%) patients defined by either lymph node (12 patients) and/or distant metastases (2 patients). Six patients with Zollinger-Ellison syndrome (ZES) required pylorus-preserving pancreaticoduodenectomy (PPPD) as initial or redo procedure and 32 patients underwent other duodenopancreatic resections. Ten (26%) patients underwent up to four reoperations for either recurrent or metastatic disease that resulted in completion pancreatectomy in four patients. After median 109 months, 44 patients were alive and three patients died, one due to thymic carcinoid and two of unrelated causes. All eight patients with organic hyperinsulinism and 7 of 13 patients with ZES were biochemically cured. However, 24 of 38 (78%) patients developed new pNENs in the pancreatic remnant, but none developed distant metastases.

Conclusions

Early resection of pNENs in MEN1 may prevent the development of distant metastases. However, the majority of patients develop new pNENs in the duodenopancreatic remnant which may require completion pancreatectomy in the long term.

Brandi ML, Gagl RF, Angeli et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671PubMedCrossRef

Trump D, Farren B, Wooding C et al (1996) Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJ Med 89:653–669

Grama D, Skogseid B, Wilander E, Eriksson B, Martensson H, Cedermark B et al (1992) Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment. World J Surg 16:611–618PubMedCrossRef

Marx S, Spiegel AM, Skarulis MC et al (1998) Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 129:484–494PubMed

Schussheim DH, Skarulis MC, Agarwal SK et al (2001) Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 12:173–178PubMedCrossRef

Carty SE, Helm AK, Amico JA et al (1998) The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 124:1106–1111PubMedCrossRef

Eriksson B, Oberg K (2000) Neuroendocrine tumours of the pancreas. BJS 87:129–131CrossRef

Gibril F, Schumann M, Pace A et al (2004) Multiple endocrine neoplasia type 1 and Zollinger–Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 83:43–83CrossRef

Waldmann J, Fendrich V, Habbe N, Bartsch DK et al (2009) Screening of patients with endocrine neoplasia type 1 (MEN-1): a critical analysis of its value. World J Surg 33:1208–1218PubMedCrossRef

10.

Thomas-Marquez L, Murat A, Delemer B et al (2006) Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 101:266–273CrossRef

11.

Goudet P, Murat A, Binquet C et al (2010) Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 34(2):249–255PubMedCrossRef

12.

Doherty GM, Olson JA, Frisella MM et al (1998) Lethality of multiple endocrine neoplasia type I. World J Surg 22:581–587PubMedCrossRef

13.

Bartsch D, Kopp I, Bergenfelz A, Rieder H, Münch K, Jäger K et al (1998) MEN1 gene mutations in 12 MEN1 families and their associated tumors. Eur J Endocrinol 139(4):416–420PubMedCrossRef

14.

Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC (1997) Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 6:1169–1175PubMedCrossRef

15.

Bartsch DK, Langer P, Wild A et al (2000) Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? Surgery 128:958–966PubMedCrossRef

16.

Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE et al (2006) Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 30(5):643–653PubMedCrossRef

17.

Schaaf L, Pickel J, Zinner K, Hering U, Höfler M, Goretzki PE et al (2007) Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. Exp Clin Endocrinol Diab 115(8):509–517CrossRef

18.

Jensen RT, Berna MJ, Bingham DB, Norton JA (2008) Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 113(7 Suppl):1807–1843PubMedCrossRef

19.

Norton JA, Alexander HR, Fraker DL et al (2001) Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger–Ellison syndrome. Ann Surg 234:495–505PubMedCrossRef

20.

Thompson NW (1998) Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger–Ellison-syndrome, hypoglycaemia or both. J Intern Med 243:495–500PubMedCrossRef

21.

Norton JA, Fraker DL, Alexander HR et al (1999) Surgery to cure the Zollinger–Ellison syndrome. N Engl J Med 341:635–644PubMedCrossRef

22.

Bartsch DK, Langer P, Fendrich V et al (2005) Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 242:757–764PubMedCrossRef

23.

Kann PH, Balakina E, Ivan D, Bartsch DK, Meyer S, Klose KJ, Behr T, Langer P (2006) Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer 13(4):1195–1202PubMedCrossRef

24.

Imamura M, Takahashi K (1993) Use of selective secretin injection test to guide surgery in patients with Zollinger Ellison syndrome. World J Surg 17:433–438PubMedCrossRef

25.

Bassi C, Dervenis C, Butturini G et al (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. International Study Group on Pancreatic Fistula Definition. Surgery 138(1):8–13PubMedCrossRef

26.

Triponez F, Dosseh D, Goudet P, Cougard P (2006) Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 243:265–272PubMedCrossRef

27.

Skogseid B et al (1998) Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab 243:489–494

28.

Gauger PG, Doherty GM, Broome JT, Miller BS, Thompson N (2009) Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms. Surgery 146:801–806PubMedCrossRef

29.

Demeure MJ, Klonoff DC, Karam JH, Duh QY, Clark OH (1991) Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. Surgery 110(6):998–1004, discussion 1004-5PubMed

30.

Akerström G, Hessman O, Skogseid B (2002) Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN1. Langenbecks Arch Surg 386:558–569PubMedCrossRef

31.

O’Riordain DS, O’Brien T, van Heerden JA, Service FJ, Grant CS (1994) Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg 18(4):488–493, discussion 493-4PubMedCrossRef

32.

Langer P, Kann PH, Fendrich V, Bartsch DK et al (2004) Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg 28:1317–1322PubMedCrossRef

33.

Tonelli F, Fratini G, Falchetti A, Nesi G, Brandi ML (2005) Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience. J Intern Med 257:38–49PubMedCrossRef

34.

Imamura M, Komoto I, Doi R, Onodera H, Kobayashi H, Kawai Y (2005) New pancreas-preserving total duodenectomy technique. World J Surg 29:203–207PubMedCrossRef

35.

Cullen JJ, Sarr MG, Ilstruup DM (1994) Pancreatic anastomotic leak after pancreaticoduodenectomy: incidence, significance and management. Am J Surg 168:295–298PubMedCrossRef

36.

Skogseid B, Rastad J, Akerstrom G Pancreatic endocrine tumors in multiple neoplasia type 1. In: Doherty GM, Skogseid B (eds) Surgical endocrinology. Lippincott Williams & Wilkins, Philadelphia, 511–525

37.

Falconi M, Plockinger U, Kwekkeboom DJ et al (2006) Consensus Conference. European Neuroendocrine Tumor Society. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 84:196–211PubMedCrossRef

38.

Fernandez-Cruz L, Cesar-Borges G (2006) Laparoscopic strategies for resection of insulinoma. J Gastrointest Surg 10:752–760PubMedCrossRef

39.

Proye CAG, Lokey JS (2004) Current concepts in functioning endocrine tumors of the pancreas. World J Surg 28:1231–1238PubMedCrossRef

40.

Lowney JK, Frisella MM, Lairmore TC, Doherty GM (1998) Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: a correlation with primary tumor size. Surgery 124:1043–1048PubMedCrossRef

41.

Lairmore TC, Chen VY, De Benedetti MK, Gillanders WE, Norton JA, Doherty GM (2000) Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 231:909–918PubMedCrossRef

42.

Cadiot G, Vuagnat A, Doukhan I, Murat A, Bonnaud G, Delemer B (1999) Prognostic factors in patients with Zollinger–Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d’Etude des Néoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d’Etude du Syndrome de Zollinger–Ellison (GRESZE). Gastroenterology 116(2):286–293PubMedCrossRef

Title: Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1
Authors: Caroline L. Lopez
Jens Waldmann
Volker Fendrich
Peter Langer
Peter H. Kann
Detlef K. Bartsch
Publication date: 01-12-2011
Publisher: Springer-Verlag
Published in: Langenbeck's Archives of Surgery / Issue 8/2011
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-011-0828-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2011

Endemic goiter—individual risk factors necessitate individual treatment

30th Annual Meeting of the German Association of Endocrine Surgeons (CAEK)

Comparison of two electromyographical endotracheal tube systems for intraoperative recurrent laryngeal nerve monitoring: reliability and side effects

The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant

Cytochrome P450-derived epoxyeicosatrienoic acids accelerate wound epithelialization and neovascularization in the hairless mouse ear wound model

Quality of life is not influenced by the extent of surgery in patients with benign goiter